Leukocyte News and Research

RSS

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422.

21 Feb 2013

Imatinib can relieve and slow down progression of multiple sclerosis

A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE.

21 Feb 2013

Healthy adults with shorter telomere length more likely to develop upper respiratory infection

Among healthy adults who were administered a cold virus, those with shorter telomere length (a structure at the end of a chromosome) in certain cells were more likely to develop experimentally-induced upper respiratory infection than participants with longer telomeres, according to results of preliminary research published in the February 20 issue of JAMA.

20 Feb 2013

University of Louisville research team explores H1N1 outbreak

Just the mention of H1N1 can conjure up images of long lines of people waiting to be vaccinated, news reports of the severity of the pandemic and the count of the number of people who perished from the 2009-10 outbreak. However, some positives are coming forward.

20 Feb 2013

CCR1 and CCR5 receptors play a crucial role in atherosclerosis

Atherosclerosis is one of the commonest causes of death in modern societies. The condition is characterized by the build-up of fatty deposits called atherosclerotic plaques on the inner surfaces of arteries, which restrict, and may eventually cut off, blood flow. The deposits can also be dislodged from their site of origin and may then block major vessels in the heart or the brain, leading to life-threatening myocardial infarction or stroke.

20 Feb 2013

Study identifies regions of genes linked to Beh-et's disease

Researchers don't know the exact cause of Beh-et's disease, a chronic condition that leads to oral and genital sores and serious complications such as blindness, but new research brings better understanding to what makes some people more susceptible to being affected.

16 Feb 2013

Study reveals how calcium signal repairs damaged tissue

For the first time scientists studying the cellular processes underlying the body's response to healing have revealed how a flash of calcium is the very first step in repairing damaged tissue. The findings, published in Current Biology, could lead to new therapies that speed up the healing process following injury or surgery.

15 Feb 2013

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

Inhibiting JNK enzyme protects against ischemic/reperfusion injury

Using two different compounds they developed, scientists from the Florida campus of The Scripps Research Institute (TSRI) have been able to show in animal models that inhibiting a specific enzyme protects heart cells and surrounding tissue against serious damage from heart attacks.

10 Feb 2013

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

10 Feb 2013

CEL-SCI reports net loss of $2,310,246 for fiscal quarter ended December 31, 2012

CEL-SCI Corporation reports financial results for the fiscal quarter ended December 31, 2012.

10 Feb 2013

Drug-carrying nanoparticles have another hurdle to overcome - escaping the bloodstream

Many medically minded researchers are in hot pursuit of designs that will allow drug-carrying nanoparticles to navigate tissues and the interiors of cells, but University of Michigan engineers have discovered that these particles have another hurdle to overcome: escaping the bloodstream.

7 Feb 2013

Oleuropein aglycone reduces inflammation associated with intestinal ischemia and reperfusion

Here's another reason why you should include olive oil in your diet: A new research report published in the Journal of Leukocyte Biology suggests that at least one compound in olive oil significantly reduces intestinal ischemia (restricted blood supply) and the resulting reperfusion injury (tissue damage caused when blood supply returns).

6 Feb 2013

Immune system can use melanoma's own proteins to kill off cancer cells

Though a small group of proteins, the family called Ras controls a large number of cellular functions, including cell growth, differentiation, and survival. And because the protein has a hand in cellular division, mutated Ras, which can be detected in one-third of all tumors, contributes to many human cancers by allowing for the rapid growth of diseased cells.

5 Feb 2013

Hope against dangerous form of acute lymphoblastic leukemia

After an intensive three-year hunt through the genome, medical researchers have pinpointed mutations that leads to drug resistance and relapse in the most common type of childhood cancer-the first time anyone has linked the disease's reemergence to specific genetic anomalies.

4 Feb 2013

Cloaked nanoparticles escape immune system surveillance to reach desired target

By cloaking nanoparticles in the membranes of white blood cells, scientists at The Methodist Hospital Research Institute may have found a way to prevent the body from recognizing and destroying them before they deliver their drug payloads. The group describes its "LeukoLike Vectors", or LLVs, in the January issue of Nature Nanotechnology.

4 Feb 2013

Temple scientists to solve long-standing mystery in sepsis

Scientists at the Center for Translational Medicine at the Temple University School of Medicine are inching closer to solving a long-standing mystery in sepsis, a complex and often life-threatening condition that affects more than 400,000 people in the U.S. every year.

28 Jan 2013

Study sheds new light on why certain people are more likely to suffer from RA

University of Michigan research sheds new light on why certain people are more likely to suffer from rheumatoid arthritis - paving the way to explore new treatments for both arthritis and other autoimmune diseases.

28 Jan 2013

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.

28 Jan 2013

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

27 Jan 2013

Leukocyte News and Research

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

Imatinib can relieve and slow down progression of multiple sclerosis

Healthy adults with shorter telomere length more likely to develop upper respiratory infection

University of Louisville research team explores H1N1 outbreak

CCR1 and CCR5 receptors play a crucial role in atherosclerosis

Study identifies regions of genes linked to Beh-et's disease

Study reveals how calcium signal repairs damaged tissue

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Inhibiting JNK enzyme protects against ischemic/reperfusion injury

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

CEL-SCI reports net loss of $2,310,246 for fiscal quarter ended December 31, 2012

Drug-carrying nanoparticles have another hurdle to overcome - escaping the bloodstream

Oleuropein aglycone reduces inflammation associated with intestinal ischemia and reperfusion

Immune system can use melanoma's own proteins to kill off cancer cells

Hope against dangerous form of acute lymphoblastic leukemia

Cloaked nanoparticles escape immune system surveillance to reach desired target

Temple scientists to solve long-standing mystery in sepsis

Study sheds new light on why certain people are more likely to suffer from RA

Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

Immunology eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News